What GeneScience Pharmaceuticals does

GeneScience Pharmaceuticals (长春金赛药业有限责任公司) is a vertically integrated Chinese biopharmaceutical company founded in 1997 and headquartered in Changchun, operating as the dominant subsidiary of state-owned Changchun High-Tech (SZ000661). The company manufactures recombinant human growth hormone products under the Saizeng® (short-acting) and Jinsaizeng® (long-acting PEG weekly) brands, holding approximately 65% historical domestic market share in China's pediatric growth hormone segment with over 100,000 patients treated. The technology foundation spans eight proprietary platforms including the U-type PEG long-acting protein platform, ultra-long-acting multi-specific antibody platform (OmniMab™), extrahepatic siRNA delivery, ADC linker-payload chemistry, T-cell engagers, protein degradation, blood-brain barrier delivery, and AI-assisted discovery.

The commercial portfolio has expanded beyond growth hormone into women's health and assisted reproductive technology (Jinsaiheng® FSH, Jinsaijia® long-acting FSH, Jin Saibei® tibolone), immunology (Firsekibart/Jinbeixin® - China's first domestic anti-IL-1β antibody for gout), allergy/respiratory (Antuoda®, Anci®, ACARIZAX® via ALK partnership), oncology supportive care (Meishiya® megestrol acetate), and oncology pipeline assets including multiple BsADC candidates (GenSci139, GenSci140, GenSci143). Distribution is executed through a 3,000-person field sales force covering 1,244 hospitals via academic promotion, complemented by NRDL reimbursement coverage, Singapore/Hong Kong/Thailand subsidiaries for Southeast Asia, e-commerce channels for the FindCare consumer nutrition brand, and international out-licensing partnerships.

The R&D operation includes 80+ pipeline programs with 40+ in clinical stage and 35+ Class 1 new drugs, supported by 1,500+ R&D personnel (70% with graduate degrees) and 10 production/R&D bases globally including US centers in San Francisco and Chicago, a European R&D center in Lausanne, and 280,000+ square meters of integrated manufacturing facilities. Annual R&D investment exceeded 23 billion CNY at 26.5% of 2025 sales, and the December 2025 $1.365 billion out-licensing of GenSci098 (TSHR antagonist) to Yarrow Bioscience validated international market value of the pipeline.

Name

GeneScience Pharmaceuticals

Legal name

长春金赛药业有限责任公司

Website

https://genscigroup.com

Company type

Private

Founded year

1997

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

GeneScience Pharmaceuticals is a vertically integrated Chinese biopharmaceutical company founded in 1997 that develops, manufactures, and commercializes recombinant growth hormones, reproductive health, immunology, and oncology biologics across pediatric, women's health, and hospital channels in 40+ countries.

Ownership category

akta.pro rank

Product category

Recombinant Biopharmaceuticals - Pediatric Endocrinology

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ)

akta.pro secondary industries

Immunology & Inflammation Pharmaceuticals (HLAIAAAD), Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB)

Keywords

• Recombinant human growth hormone
• Long-acting biologics
• Assisted reproductive technology
• Antibody-drug conjugates
• Pediatric endocrinology

Headquarters

HQ city

Changchun

HQ country

China

HQ region

Asia

Offices11 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Marketing or Sales, Operations, Supply Chain, Infrastructure

Revenue model

1. Pharmaceutical Products Sales: Core revenue from sales of growth hormone series (赛增®, 金赛增®), reproductive health drugs (金赛恒®, 金赛佳®), gout treatment (金蓓欣®/伏欣奇拜单抗), allergy/AIT products (安脱达®, 安刺®), oncology support drugs (美适亚®), and other innovative drugs across ~30+ commercialized products.
2. International Licensing/BD Revenue: Overseas out-licensing deals for proprietary pipeline molecules. GenSci098 (TSHR antagonist antibody, also known as YB-101) licensed to Yarrow Bioscience for $1.365 billion (December 2025). Represents a third growth engine alongside growth hormone and domestic innovative drugs.
3. Consumer Health/Nutrition Products: FindCare brand nutritional supplements (赖氨酸成长粉, 赖氨酸复合成长饮, 赖氨酸成长胶囊, PS脑营养胶囊) sold via e-commerce platforms (Tmall, JD) and direct online channels, targeting parents of children aged 3+.

Pricing tiers

Go-to-market motion3 records

Distribution channels5 records

Marketing channels8 records

Core offering

GeneScience Pharmaceuticals develops, manufactures, and commercializes recombinant human growth hormone products (short-acting and the world's first PEGylated long-acting weekly formulation), reproductive health biologics (recombinant and long-acting FSH, progesterone), China's first domestic anti-IL-1β monoclonal antibody for gout, nano-crystal megestrol acetate for cancer cachexia, allergen immunotherapy products, and consumer children's nutritional supplements under the FindCare brand. The portfolio includes 30+ commercialized products and 80+ pipeline programs spanning endocrinology, women's health, immunology, oncology, respiratory, ophthalmology, neurology, nephrology, dermatology, and digestive diseases.

Product overview

GeneScience Pharmaceuticals (金赛药业) is a fully integrated biopharmaceutical company headquartered in Changchun, China, with operations spanning drug R&D, manufacturing, and commercial sales. The company has established leadership in endocrinology with its growth hormone franchise (赛增, 金赛增) and reproductive health products (金赛恒, 金赛佳), while expanding into immunology (Firsekibart/伏欣奇拜单抗 for gout), oncology (multiple ADC candidates including GenSci143, GenSci139, GenSci140), and respiratory medicine. The portfolio includes 30+ marketed products and 80+ R&D pipelines with 40+ in clinical stage. The company operates three major production bases: Growth Hormone Industrial Park (45,000㎡), International Pharmaceutical Industrial Park (120,000㎡), and Chemical Pharmaceutical Raw Material Park (140,000㎡). Technology platforms include ultra-long-acting multispecific antibodies, extrahepatic siRNA delivery, long-acting sustained-release peptides, ADC, T-cell engagers (TCE), protein degradation, blood-brain barrier delivery, and裂解酶. The company has also developed a nutritional supplements sub-brand FindCare applying Nobel Prize-winning circadian rhythm research for children's growth products.

Differentiator

Problem solved

Functional benefit

Brands

• FindCare: Children's nutritional supplement brand under GeneScience, offering lysine-based growth products (FindCare赖氨酸成长粉, FindCare赖氨酸复合成长饮, FindCare赖氨酸成长胶囊) and PS brain nutrition capsules, applying Nobel laureate Jeffrey Hall's circadian rhythm research.

Products and services

• Saizeng (赛增) Recombinant Human Growth Hormone for Injection (powder) First domestically developed recombinant human growth hormone (rhGH) powder injection approved in 1998 in China, for treatment of growth hormone deficiency and related growth disorders in children.
• Saizeng (赛增) Recombinant Human Growth Hormone Injection (aqueous solution) Asia's first aqueous recombinant human growth hormone (rhGH) injection for treatment of growth hormone deficiency and related growth disorders in children.
• Jinsai Zeng (金赛增) PEGylated Long-Acting Recombinant Human Growth Hormone Injection World's first PEGylated long-acting weekly injection of recombinant human growth hormone, applied to pediatric endocrinology departments and hospitals across China, reducing injection frequency from daily to weekly while maintaining efficacy.
• Jinsai Heng (金赛恒) Recombinant Human Follicle-Stimulating Hormone for Injection China's first domestically developed recombinant human follicle-stimulating hormone (rhFSH) for controlled ovarian stimulation in assisted reproductive technology, breaking import dependency in ART.
• Saizeng (赛增) Recombinant Human Follicle-Stimulating Hormone Injection Recombinant human follicle-stimulating hormone (rhFSH) injection formulation for controlled ovarian stimulation in assisted reproductive technology.
• Jinsai Jia (金赛佳) Long-Acting Recombinant FSH-CTP Fusion Protein Injection Long-acting recombinant FSH-CTP fusion protein injection for controlled ovarian stimulation in IVF, providing 7-day efficacy from a single injection and reducing injection burden in ART treatment cycles.
• Meishi Ya (美适亚) Megestrol Acetate Oral Suspension Nano-crystal megestrol acetate oral suspension for cancer anorexia-cachexia syndrome (CACS), improving appetite and weight gain with faster onset and better bioavailability than conventional formulations; affects over one-third of cancer patients.
• Jinbei Xin / Firsekibart (金蓓欣) Firsekibart Injection China's first domestically developed fully human anti-IL-1β monoclonal antibody for acute gouty arthritis, reducing recurrence risk by approximately 87-90% with twice-yearly subcutaneous injection dosing; sJIA Phase II showed 94.1% ACR Pedi 30 response at Day 28.
• Andetoda (安脱达) House Dust Mite Allergen Extract for Subcutaneous Immunotherapy House dust mite allergen extract for subcutaneous immunotherapy (SCIT) of allergic rhinitis and asthma, partnered with ALK-Abelló for China distribution under 2025 strategic agreement.
• Anci (安刺) Dust Mite Allergen Skin Prick Test Kit Dust mite allergen skin prick test kit for the diagnosis of dust mite allergies, distributed in mainland China under the ALK-Abelló partnership.
• ACARIZAX (尘螨变应原舌下片) Dust Mite Allergen Sublingual Tablet Dust mite allergen sublingual immunotherapy tablet partnered with ALK-Abelló for desensitization therapy in allergic rhinitis and asthma across mainland China.
• Jinsai Bei (金赛贝) Tibolone Tablets Generic tibolone tablets for menopausal hormone therapy, the first to pass bioequivalence evaluation compared to the original product, supporting women's health across perimenopause and post-menopause.
• FindCare Lysine Growth Powder (FindCare 赖氨酸成长粉) Lysine-based children's growth nutritional supplement powder (6g×30 bags/box) for children aged 3+, with 4 amino acid growth factors, calcium, magnesium, zinc, and vitamin D3, applying Nobel laureate Jeffrey C. Hall's circadian rhythm research.
• FindCare Lysine Complex Growth Drink (FindCare 赖氨酸复合成长饮) Liquid lysine complex growth drink (25mL×15 bags/box) with 600mg liquid lysine, 4 amino acid growth factors, organic calcium/magnesium/zinc/VD3 for children's growth support.
• FindCare Lysine Growth Capsules (FindCare 赖氨酸成长胶囊) Lysine growth capsules (60 capsules/bottle) for children aged 6+, with 600mg lysine, 4 amino acid growth factors, and VD3.
• FindCare PS Brain Nutrition Capsules (FindCare PS脑营养胶囊) Phosphatidylserine (PS) brain nutrition capsules (60 capsules/bottle) with 8 brain factors and 100mg high-content PS for children aged 6+.

Quantifiable outcome

• Long-acting growth hormone (金赛增®) Phase III: annualized growth rate 13.41 cm/year, significantly superior to short-acting formulations with good safety profile
• +7 more outcomes

Named customers6 records

Segments6 records

Ideal customer profiles5 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature7 records

Partnerships

19 partnerships are on record, tiered minor and core.

• 温州医科大学minorStrategic or Co-development Partner · 5 June 2026温州医科大学联合金赛药业等6家单位获批国家科技重大专项，合力深耕生物医药创新。
• 阿里健康 (Alibaba Health)minorStrategic or Co-development Partner · 1 January 2026金赛药业与阿里健康达成战略合作，共同开启智慧医疗新篇章，在数字医疗、慢病管理、在线药房等领域展开深度合作。
• Yarrow Bioscience, Inc. (RTW Investments subsidiary)coreStrategic or Co-development Partner · 15 December 2025金赛药业全资子公司上海赛增医疗科技有限公司与美国生物医药公司Yarrow Bioscience签署独家许可协议。Yarrow获得金赛药业自主研发的人源化TSHR拮抗型单克隆抗体GenSci098(YB-101)在大中华区以外的全球独家开发、生产和商业化权利。交易总额高达13.65亿美元，包括首付款、开发和监管里程碑及销售里程碑款项。此授权标志着公司创新成果获国际认可。
• Partex AI (全球领先AI公司)coreTechnology or Integration · 1 December 2025金赛药业携手全球领先AI公司Partex AI，在药物研发与海外商业化领域展开战略合作，加速创新药物从分子设计到临床转化的全流程智能化升级，共同推动创新药物的全球化开发与商业化进程。
• 京东健康 (JD Health)minorStrategic or Co-development Partner · 1 November 2025金赛药业与京东健康达成战略合作，共创数字医疗新未来，在互联网医疗、健康管理、药品供应链等领域展开合作。
• ALK-Abelló A/S (丹麦)coreStrategic or Co-development Partner · 17 September 2025金赛药业与全球最大脱敏治疗药企ALK签署合作协议，获得ALK自主开发的3款脱敏治疗产品在中国大陆（不含港澳台）的独家代理权益，包括安脱达®(屋尘螨变应原制剂)、安刺®(螨变应原皮肤点刺试剂盒)及ACARIZAX®(尘螨变应原舌下片)。合作还涉及双方联合开发并商业化ALK的变应原特异性免疫治疗(AIT)产品，合作期限至2039年12月31日。
• 逸达生物科技股份有限公司 (Taiwan)coreStrategic or Co-development Partner · 1 September 2025金赛药业与逸达生物科技合作亮丙瑞林注射乳剂(CAMCEVI®)中国区(除台湾)权益。该产品采用储库型原位凝胶技术，实现6个月给药间隔，用于晚期前列腺癌雄激素去势治疗。III期临床研究结果在《中华泌尿外科杂志》发表。
• JPMorgan Chase (摩根大通)minorOthers · 1 January 2025金赛药业研发及商业化团队代表应邀出席第44届摩根大通医疗健康年会(JPM大会)，公司副总裁夏远峰博士发表主题演讲，展示公司创新研发平台和重点管线。
• 浙江大学minorStrategic or Co-development Partner · 1 April 2024浙江大学-金赛药业儿童健康联合研究中心签约成立。'金赛博爱奖学金'在浙江大学生命科学学院举行颁奖仪式。
• 上海交通大学minorStrategic or Co-development Partner · 1 March 2024金赛药业与上海交通大学共建'数字医疗创新实验室'，开展数字化医疗技术研究。'金赛博爱奖学金'在上海交通大学生命科学技术学院颁发。
• 上海交通大学minorStrategic or Co-development Partner · 1 January 2021上海交通大学与金赛药业共建'数字医疗创新实验室'，聚焦AI辅助药物发现、数字医疗技术等前沿领域。
• TWi Pharmaceuticals, Inc.coreChannel Partner/ Reseller/ Distributor金赛药业新加坡公司与TWi Pharmaceuticals达成美适亚®(醋酸甲地孕酮口服混悬液)授权经销合作协议。TWi授权金赛药业新加坡公司为中国大陆、香港、澳门地区及新加坡唯一总经销商，负责该产品的市场营销与推广。
• 清华大学minorStrategic or Co-development Partner中国红十字基金会金赛员工公益基金'金赛博爱奖学金'在清华大学举行颁奖仪式，金赛药业中央研究院抗体发现与蛋白工程副总裁雷鸣等出席。清华大学生命科学学院实践队受邀赴长春金赛调研。
• 北京大学minorStrategic or Co-development Partner金赛药业与北京大学开展'金赛博爱奖学金'合作，北京大学生命科学学院2024届毕业生草坪音乐会获金赛药业首席赞助。金赛药业参与北京大学医学部医院品牌建设训练营。
• 武汉市儿童医院minorStrategic or Co-development Partner武汉儿童医院与金赛药业共建创新成果转化联合平台，共同推进儿科领域的科研成果转化与临床应用。
• 上海市儿童医院minorStrategic or Co-development Partner上海市儿童医院与金赛药业携手，共同按下科研创新加速键，在儿童健康领域开展创新成果转化合作。
• 健康报社 (Health Newspaper)minorGTM or Marketing Partner金赛药业与健康报社签订战略合作协议，共同推进妇儿健康科普教育、健康中国行动宣传及医疗机构品牌建设等领域的合作。
• 微医集团 (WeDoctor)minorGTM or Marketing Partner金赛药业与微医集团签署'妇儿护航计划'战略合作意向书，共建数字化专科健康服务体系，合作开发妇儿健康护航平台的配套产品与服务。
• 中国红十字基金会coreOthers金赛药业自2010年起联合中国红十字基金会设立'成长天使基金'，累计救助贫困矮小患者超3,900人，药物捐赠总价值3.63亿元。长期支持小胖威利综合征关爱项目，救助超1,000人次。连续16年公益投入，被授予'人道奉献伙伴'。

Scale indicators10 records

Recent moves10 records

Expansion highlights6 records

Direct peers

• Novo Nordisk: Global leader in growth hormone therapy (Norditropin, Sogroya) and broader endocrine/metabolic disease portfolio. Directly comparable to GeneScience in growth hormone market positioning, long-acting technology platforms, and pediatric endocrinology focus.
• Ipsen: Specialty biopharmaceutical company with growth hormone franchise (Increlex) and similar endocrinology/reproductive health focus. Comparable in product portfolio strategy targeting niche specialty endocrinology indications.
• Merck KGaA (Life Science / Healthcare): Markets Gonal-f (recombinant FSH), a leading reproductive health product for ART. Directly comparable to GeneScience's Jinsai Heng/Jinsai Jia FSH franchise in the assisted reproduction market.
• Organon: Women's health-focused pharmaceutical company spun from Merck, with reproductive health portfolio (Ganirelix, Follistim) and growing menopause/endocrine franchises. Highly comparable to GeneScience's women's health strategy.

Broad incumbents

• Pfizer (Genotropin): Markets Genotropin (somatropin) growth hormone. While a broad pharmaceutical incumbent, it competes directly in the growth hormone space globally and has similar reproductive health heritage.
• Innovent Biologics: Leading Chinese innovative biopharmaceutical company with biologic and biosimilar portfolio. Comparable as a Chinese domestic competitor building innovative drug pipeline and commercial infrastructure, though focused more on oncology.
• BeiGene: Major Chinese innovative biopharmaceutical company with global commercial presence (Brukinsa) and broad oncology pipeline. Comparable as a Chinese innovator pursuing international out-licensing strategy similar to GeneScience's Yarrow deal.
• Hansoh Pharmaceutical: Large Chinese innovative pharmaceutical company with oncology, CNS, and endocrine franchises. Comparable as a domestic competitor with similar R&D intensity and commercial scale in China.

Emerging players

• Daiichi Sankyo: Japanese pharmaceutical innovator with leading ADC platform (Enhertu). Comparable in ADC technology platform development, though at more advanced commercial stage — relevant for benchmarking GeneScience's BsADC pipeline potential.
• ALK-Abelló: Global leader in allergy immunotherapy (AIT). GeneScience is ALK's exclusive distribution partner for 3 AIT products in mainland China, making them a strategic partner-peer in the allergy/respiratory segment.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Subsidiaries7 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about GeneScience Pharmaceuticals